Randomized Trial of Pharmacokinetic and Pharmacodynamic Effects of 13.2 mg Intranasal Epinephrine Treatment in Congestion
David A. Dworaczyk,Allen Hunt,Mike Di Spirito,Mary Lor,Karen Rance,Aernout D. van Haarst
DOI: https://doi.org/10.1016/j.anai.2024.04.033
2024-05-08
Abstract:Background: Nasal congestion could affect the absorption of an epinephrine nasal spray (ENS). Objective: To compare the pharmacokinetics of 13.2 mg ENS with nasal congestion to without congestion and to intramuscular (IM) treatments. Methods: This Phase I, open-label, 4-period randomized crossover study enrolled 51 healthy adults with seasonal allergies into cohorts that received a single dose of 13.2 mg ENS (NDS1C) administered as 2 consecutive sprays in either opposite nostrils (Cohort 1) or the same nostril (Cohort 2). Both cohorts received 13.2 mg ENS with and without nasal allergen challenge (NAC), 0.3 mg IM epinephrine by autoinjector, and 0.5 mg IM epinephrine by manual syringe (MS). Results: ENS after NAC resulted in higher extent and peak exposures and more rapid time to maximum plasma concentration (Tmax) versus ENS without NAC and IM treatments. In Cohort 1, maximum observed baseline-adjusted epinephrine plasma concentration (Cmax, pg/mL) with ENS with NAC, IM autoinjector, IM MS, or ENS without NAC was 458.0, 279.0, 364.2, and 270.1, respectively, and in Cohort 2 was 436.3, 228.2, 322.3, and 250.8, respectively. The Cmax geometric mean ratio (90% CI) for ENS with NAC versus without NAC in Cohort 1 was 170% (123%, 234%) and in Cohort 2 was 174% (115%, 263%). In Cohort 1, Tmax was 15, 21, 45, and 25 minutes, respectively, and in Cohort 2 was 18, 20, 45, and 20 minutes, respectively (p<0.01 for ENS with NAC vs IM MS). Postdose mean heart rate and blood pressure remained stable and relatively similar to predose values regardless of plasma epinephrine concentration. Mild nausea and headache were the most common adverse events with ENS. Conclusion: 13.2 mg ENS with congestion demonstrated enhanced absorption versus IM treatments and ENS without congestion and appeared well tolerated. There was no clinically impactful relationship between pharmacodynamic effects and plasma epinephrine concentration.
immunology,allergy